Chemotherapy for human epidermal growth factor receptor type2 (HER2)-positive breast cancer involves pertuzumab (PER) and trastuzumab (TRA) with docetaxel (DTX) (PHD) or paclitaxel (PTX) (PHP) regimens. Here, ERBB2 is linked to breast cancer.